Association of adipose tissue mediators with the development of cancer in patients with metabolic syndrome
-
Published:2024-05-12
Issue:2
Volume:23
Page:101-110
-
ISSN:2312-3168
-
Container-title:Siberian journal of oncology
-
language:
-
Short-container-title:Sib. onkol. ž.
Author:
Sereda E. E.1ORCID, Chernyshova A. L.2ORCID, Mamonova T. Yu.2, Kakurina G. V.1ORCID, Yunusova N. V.1ORCID, Sidenko E. A.1ORCID, Korshunov D. A.2ORCID, Kondakova I. V.2ORCID
Affiliation:
1. Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University of The Ministry of Health of Russia 2. Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Abstract
The aim of the study was to summarize the available data on the relationship between adipose tissue mediators and cancer in patients with metabolic syndrome. Material and methods. A literature search was conducted using the PubMed and eliBRARY databases. Of the 400 articles published over the past 20 years, 58 studies were included in the review. Results. There is evidence of an unfavorable course of cancer in patients with metabolic syndrome that is explained by the presence of common pathogenetic pathways. In this review, special attention is paid to adipose tissue mediators that regulate the course of inflammation. The involvement of adipose tissue mediators in the pathogenesis of cancer is discussed. The relationship between adipokines of adipose tissue and the effects of specialized pro-resolving mediators (SpRM), which are metabolites of polyunsaturated fatty acids (resolvins, protectins and maresins), are considered. the associations of mediators that regulate the intensity of inflammation with the metabolic syndrome and cancer are discussed. Conclusion. Further studies will contribute to a better understanding of the relationship between metabolic syndrome and cancer and the search for adequate predictive markers to select the most effective drug strategy for correcting metabolic syndrome.
Publisher
Tomsk Cancer Research Institute
Reference58 articles.
1. Mili N., Paschou S.A., Goulis D.G., Dimopoulos M.A., Lambrinoudaki I., Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021; 74(3):478–97. doi: 10.1007/s12020-021-02884-x. 2. Recommendations for the management of patients with metabolic syndrome developed on behalf of the Russian Ministry of Health and approved by the Russian Medical Society forArterial Hypertension and the Specialized Commission on Cardiology. Moscow, 2013. (in Russian). 3. Chernyshova A.L., Kolomiets L.A., Yunusova N.V., Shanshashvili Е.V. Hormonal and energetic changes in patients with endometrial hyperplasia and endometrial cancer. Siberian Journal of Oncology. 2015;1(1): 5–12. (in Russian). 4. Yunusova N.V., Kondakova I.V., Kolomiets L.A., Afanas’ev S.G., Kishkina A.Y., Spirina L.V. The role of metabolic syndrome variant in the malignant tumors progression. Diabetes Metab Syndr. 2018; 12(5): 807–12. doi: 10.1016/j.dsx.2018.04.028. 5. Conteduca V., Caffo O., Galli L., Maugeri A., Scarpi E., Maines F., Chiuri V.E., Lolli C., Kinspergher S., Schepisi G., Santoni M., Santini D., Fratino L., Burgio S.L., Salvi S., Menna C., De Giorgi U. Association among metabolic syndrome, inflammation, and survival in prostate cancer. Urol Oncol. 2018; 36(5). doi: 10.1016/j.urolonc.2018.01.007.
|
|